(CercleFinance.com) – While maintaining its ‘neutral’ opinion on Ipsen, Oddo BHF raises its target price from 102 to 115 euros (i.e. an upside potential of 9%), after having factored in its new projections for the pharmaceutical company French.
“We clearly see the effect of the reinforcement of the pipeline made possible by the new strategy, but we fear the loss of momentum of Somatuline and its effect not yet compensated by the other products, in the short term, on the margins”, affirms the analyst.
According to him, the multiples are modest, but above all they reflect the generic threat which has never been so significant. “This transition/preparation profile invites us to be cautious, even if Ipsen usually guides cautiously,” he concludes.
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
